<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648517</url>
  </required_header>
  <id_info>
    <org_study_id>4-2008-0132</org_study_id>
    <nct_id>NCT01648517</nct_id>
  </id_info>
  <brief_title>Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 &amp; RRM1 as First-line Chemotherapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective phase II trial, in patients with unresectable or metastatic NSCLC using
      chemotherapy regimens which will be defined according to the mRNA expression of ERCC1 and
      RRM1 of the tumor cells.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2012</start_date>
  <completion_date type="Actual">June 30, 2015</completion_date>
  <primary_completion_date type="Actual">June 30, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall Response Rate</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>ORR was assessed by tumor response evaluation according to RECIST 1.1 at every 8 weeks. Tumor assessments will continue about every 8 weeks until disease progression or initiation of subsequent anticancer treatment.
(If PR or CR was first documented, confirmation assessment was done between 4 weeks and 8 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genomic-driven dual agent chemotherapy Chemotherapy will consist of the assigned two drugs according to ERCC1 and RRM1 mRNA expression level A1: docetaxel + vinorelbine (DV) A2: gemcitabine + vinorelbine (GV) A3: docetaxel + carboplatin (DC) A4: gemcitabine + carboplatin (GC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard of care All control arm patients received standard platinum-based doublet chemotherapy with docetaxel plus carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Docetaxel - Taxotere</other_name>
    <other_name>Vinorelbine: Sandoz vinorelbine</other_name>
    <other_name>Carboplatin: Carplan</other_name>
    <other_name>Gemcitabine: Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Docetaxel - Taxotere</other_name>
    <other_name>Carboplatin: Carplan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed unresectable advanced or metastatic non-small cell lung
             cancer (NSCLC) (stage IIIB or IV)

          2. Chemotherapy naïve patient (Previous adjuvant or neoadjuvant chemotherapy allowed if
             the last dose was administered equal to or greater than 6 months ago.)

          3. Age &gt; 18

          4. Performance status 0 to 2 by Eastern Cooperative Oncology Group (ECOG) criteria

          5. At least one measurable lesion by Response Evaluation Criteria In Solid Tumors
             (RECIST)

          6. Adequate organ functions (assessed within 14 days of starting treatment) 1) Bone
             marrow: Absolute neutrophil count ≥ 1,500/mm³, Platelet count ≥ 100,000/mm³,
             Hemoglobin ≥ 9.0 mg/dL 2) Liver: Total bilirubin ≤ 1.5 x ULN; aspartic transaminase
             (AST) and alanine transaminase (ALT), alkaline phosphatase(ALP) ≤ 2.5 x ULN 3) Kidney:
             Serum creatinine ≤ 1.5 x ULN

          7. Signed informed consent document

        Exclusion Criteria:

          1. Clinically significant serious illness or medical condition (infection)

          2. Prior systemic chemotherapy or immunotherapy for advanced NSCLC.

          3. Presence of uncontrolled brain or leptomeningeal metastases

          4. Prior radiotherapy within 3 weeks of starting treatment

          5. Peripheral neuropathy equal to or greater than grade 2 by Common Terminology Criteria
             for Adverse Events (CTCAE) v4.0

          6. Pregnant or lactating

          7. Absolute contraindication of corticosteroid use

          8. Patients with a history of severe hypersensitivity reaction to docetaxel, carboplatin,
             vinorelbine or gemcitabine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>November 26, 2017</last_update_submitted>
  <last_update_submitted_qc>November 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>on-small cell lung carcinoma</keyword>
  <keyword>chemotherapy naive patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

